Open AccessEfficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy
Author(s) -
Karine Lacombe,
Nadia Valin,
Hind Stitou,
Joël Gozlan,
Vincent Thibault,
Anders Boyd,
JeanMarie Poirier,
JeanLuc Meynard,
MarcAntoine Valantin,
J. Bottéro,
PierreMarie Girard
Publication year - 2013
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32836138d0
Subject(s) - telaprevir , ribavirin , medicine , pegylated interferon , hepatitis c virus , genotype , hepacivirus , hepatitis c , gastroenterology , virology , virus , biology , gene , biochemistry
The efficacy and tolerance of telaprevir (TVR) was examined in 20 mostly cirrhotic HIV-hepatitis C genotype 1 (HCV-G1)-infected patients failing previous treatment with pegylated-interferon and ribavirin (PR). HCV-RNA less than 12 IU/ml was observed in 35.3% of patients at W2, 55.0% at W4, 65.0% at W12 and 55.0% at W24. All patients with virological failure (n = 9) exhibited V36M/R155K mutations. Early virological response was a determinant of HCV-RNA less than 12 IU/ml at W24 (P < 0.001). No grade 3-4 dermatological side-effects were reported. TVR-PR tritherapy appeared to be rather effective and well tolerated among difficult-to-treat HIV-HCV-G1 patients.